Stenting of Coronary Arteries in Non Stress/Benestent Disease SCANDSTENT Trial Stenting of Coronary Arteries in Non Stress/Benestent Disease Presented at American College of Cardiology Scientific Sessions 2005 Presented by Dr. Henning Kelbæk

SCANDSTENT Trial 322 stable angina, unstable angina, or non-ST elevation MI patients with complex lesions (occluded, bifurcational, ostial, or angulated) Randomized Sirolimus-eluting Stent (SES) n=163 Bare Metal Stent (BMS) n=159 Endpoints (6 months): Minimum lumen diameter and angiographic restenosis (>50%) Presented at ACC Scientific Sessions 2005

Target Lesion Revascularization SCANDSTENT Trial Death p=NS MI p=NS Stent Thrombosis p=NS Target Lesion Revascularization p<0.001 MACE p<0.001 % SES BMS SES BMS SES BMS SES BMS SES BMS There were no differences by treatment group in the clinical endpoints of death, MI, or stent thrombosis. Target lesion revascularization was significantly lower in the SES group, and as a result, overall MACE was lower in the SES group. Presented at ACC Scientific Sessions 2005

Minimum Lumen Diameter SCANDSTENT Trial 6 Month Angiographic Follow-up Minimum Lumen Diameter p<0.0001 Late Lumen Loss p<0.0001 % Diameter Stenosis p<0.0001 Binary Restenosis p<0.0001 SES BMS SES BMS SES BMS SES BMS On 6 month angiographic follow-up, minimum lumen diameter was larger in the SES group than BMS group as was late lumen loss. Both percent diameter stenosis and binary restenosis were lower in the SES group compared with the BMS group. Presented at ACC Scientific Sessions 2005

SCANDSTENT Trial: Summary Among patients with complex lesions, use of sirolimus-eluting stents was associated with a reduction in target lesion revascularization and improvements in diameter stenosis at 6 month follow-up compared with bare metal stents. Prior studies such as SIRIUS have shown a similar benefit with sirolimus-eluting stents over bare metal stents in patients with simple de novo lesions. Additionally, a prior study by Colombo, et al reported a benefit in bifurcation lesions. Finally, the TAXUS V trial recently demonstrated a reduction in target vessel revascularization with paclitaxel-eluting stents for a variety of complex coronary lesions. As with other drug-eluting stent trials, improvements were seen in target lesion revascularization and restenosis but no difference was observed in other clinical events. Presented at ACC Scientific Sessions 2005